Triglycerides as a risk factor for coronary artery disease

American Journal of Cardiology

Volumn 82, Issue 12 A, 1998, Pages

  Sprecher, Dennis L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA ANALYSIS; DISEASE ASSOCIATION; HUMAN; LIPID METABOLISM; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032542326     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00953-9     Document Type: Conference Paper

References (20)

1. Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
2. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med 1996;124:515-517.
3. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. Arch Intern Med 1959;103:4-8.
4. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70(suppl):3H-9H.
5. Austin MA, Hokanson JE. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am (Lipid Disorders) 1994;78:99-115.
6. Bainton D, Miller NE, Bolton CH, Yarnell JWG, Sweetnam PM, Baker IA, Lewis B, Elwood PC. Plasma triglyceride and high-density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 1992;68:60-66.
7. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Res 1996; 3:213-219.
8. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb Vasc Biol 1992;12:1336-1345.
9. Sprecher DL, Knauer SL, Black DM, Kaplan LA, Akeson AA, Dusing M, Lattier D, Stein EA, Rymaszewski M, Wiginton DA. Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families. J Clin Invest 1991;88:985-994.
10. Ashbourne Excoffon KJD, Liu G, Miao L, Wilson JE, McManus BM, Semenkovich CF, Coleman T, Benoit P, Duverger N, Branellec D, Denefle P, Hayden MR, Lewis MES. Correction of hypertriglyceridemia and impaired fat tolerance in lipoprotein lipase-deficient mice by adenovirus-mediated expression of human lipoprotein lipase. Arterioscler Thromb Vasc Biol 1997;17:2532-2539.
11. Chiba T, Miura S, Sawamura F, Uetsuka R, Tomita I, Inoue Y, Tsutsumi K, Tomita T. Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Arterioscler Thromb Vasc Biol 1997;17:2601-2608.
12. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
13. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation 1990;81:470-476.
14. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
15. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
16. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
17. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesäniemi YA, Pasternack A, Taskinen M-R, for the Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997;96:2137-2143.
18. Gianturco SH, Bradley WA, Gotto AM Jr. Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation mouse peritoneal macrophages. J Clin Invest 1982;70:168-176.
19. Sprecher DL, Harris BV, Stein EA, Bellet PS, Keilson LM, Simbartl LA. Higher triglycerides, lower high-density lipoprotein cholesterol, and higher systolic blood pressure in lipoprotein lipase-deficient heterozygotes: a preliminary report. Circulation 1996;94:3239-3245.
20. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998;18:20-26.